Background:

Thromboxane B₂-d₉(TXB₂-d₉) is intended for use as an internal standard for the quantification of TXB₂by GC- or LC-MS. TXB₂is a non-enzymatically derived, stable, inactive metabolite of TXA₂, which is highly unstable.^1,2,3Serum levels of TXB₂positively correlate with platelet COX-1 activation.^4,5Urinary levels of TXB₂reflect intrarenal TXA₂synthesis, while its metabolites, 11-dehydro TXB₂and 2,3-dinor TXB₂, reflect systemic TXA₂secretion.^2,6,7
TXB₂-d₉MaxSpec^?standard is a quantitative grade standard of TXB₂-d₉that has been prepared specifically for mass spectrometry and related applications where quantitative reproducibility is required. The solution has been prepared gravimetrically and is supplied in a deactivated glass ampule sealed under argon. The concentration was verified by comparison to an independently prepared calibration standard. This TXB₂-d₉MaxSpec^?standard is guaranteed to meet identity, purity, stability, and concentration specifications and is provided with a batch-specific certificate of analysis. Ongoing stability testing is performed to ensure the concentration remains accurate throughout the shelf life of the product.Note: The amount of solution added to the vial is in excess of the listed amount. Therefore, it is necessary to accurately measure volumes for preparation of calibration standards. Follow recommended storage and handling conditions to maintain product quality.

1.Needleman, P., Moncada, S., Bunting, S., et al.Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxidesNature261(5561)558-560(1976) 2.Patrono, C., Ciabattoni, G., Pugliese, F., et al.Estimated rate of thromboxane secretion into the circulation of normal humansJ. Clin. Invest.77(2)590-594(1986) 3.Uyama, O., Matsumoto, M., Fujisawa, A., et al.Plasma concentrations of thromboxane B2 in patients with hypertension or cerebrovascular diseaseProstaglandins Med.7(3)199-207(1981) 4.Arantes, F.B.B., Menezes, F.R., Franci, A., et al.Influence of direct thrombin inhibitor and low molecular weight heparin on platelet function in patients with coronary artery disease: A prospective interventional trialAdv. Ther.37(1)420-430(2020) 5.Ferroni, P., Riondino, S., Vazzana, N., et al.Biomarkers of platelet activation in acute coronary syndromesThromb. Haemost.108(6)1109-1123(2012) 6.Patrono, C., Ciabattoni, G., Patrignani, P., et al.Evidence for a renal origin of urinary thromboxane B2 in health and diseaseAdv. Prostaglandin Thromboxane Leukot. Res.11493-498(1983) 7.Lawson, J.A., Patrono, C., Ciabattoni, G., et al.Long-lived enzymatic metabolites of thromboxane B2 in the human circulationAnal. Biochem.155(1)198-205(1986)